Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma

Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma

ABSTRACT Backgroud Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over‐expression. Case We report the case o...

Full description

Saved in:
Bibliographic Details
Main Authors: Martina Napolitano, Lucia Trudu, Enrica Martinelli, Chiara Santini, Massimo Dominici, Federica Bertolini
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Cancer Reports
Subjects:
head and neck
HER2 targeted therapy
neratinib
precision medicine
salivary duct carcinoma
Online Access:https://doi.org/10.1002/cnr2.70065
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items